Analysts have touted the market potential of Xenon Pharmaceuticals’ novel epilepsy drug, azetukalner, following a positive late-stage readout in patients with focal onset seizures (FOS).
During the global, Phase III X-TOLE2 study (NCT05614063), both a high (25mg) and low (15mg) dose of azetukalner met the trial’s primary endpoint, reducing the monthly frequency of FOS by 53.2% and 34.5% from baseline at week 12. This compares with a 10.4% reduction in FOS observed in patients given the placebo.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to William Blair analyst Miles Minter, results from the X-TOLE2 study “blow away” the company’s expectations of ≥30% placebo-normalised improvement. Analysts at echoed this sentiment, noting that azetukalner’s efficacy has “beaten already-high Street expectations”.
Other investors also seem optimistic about these results, as Xenon’s stock value climbed 44% from $41.94 at market close on 6 March to $60.56 at opening on 9 March.
Alongside clearing the efficacy bar set by investors, the Phase III trial on azetukalner also showed that the drug improved FOS outcomes over time. This was evidenced by the FOS reduction of 52.8% and 18.2% observed within the 25mg and 15mg dose cohorts, respectively, at eight weeks in the drug’s Phase IIb trial.
Azetukalner’s safety and tolerability profile remained consistent with prior studies conducted on the potassium channel opener, with the most common adverse events (AEs) being dizziness, somnolence and headache.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe therapy acts by opening Kv7.2/Kv7.3 potassium channels found across the neuronal membrane, which constitutes a novel mechanism of action (MoA) in epilepsy. By keeping these channels open longer, azetukalner can reduce the excitability of neurones – dampening the prevalence of seizure-causing stimulation.
Next steps for azetukalner
Following the positive outcome of the X-TOLE2 study, Xenon is eyeing regulatory approval for azetukalner. In Q3 2026, the biotech plans to submit a New Drug Application (NDA) to US regulators for the drug in FOS, which could see the drug become the first potassium channel opener to gain approval in this indication.
Currently, the standard of care (SoC) for epilepsy with FOS is anti-seizure medications, with several having different mechanisms of action. While drugs like sodium channel inhibitors can offer significant benefits for some patients, the Epilepsy Research Institute UK currently estimates that 30% of patients with epilepsy live with uncontrolled seizures, despite the availability of medications.
In a 9 March investor call, Xenon’s president and CEO, Ian Mortimer, celebrated the results, noting that, to the company’s knowledge, azetukalner’s placebo-adjusted efficacy is the “highest ever observed in a pivotal epilepsy study”.
Minter also touted the azetukalner’s safety and administration profile, adding that the “single pill, no titration, no drug-drug interaction profile” could further champion its potential growth within the epilepsy market.
When asked how the drug would fit into the treatment paradigm if approved, Mortimer said that azetukalner would likely hold a place on the refractory market to begin with. However, Mortimer anticipates that the data and azetukalner’s novel mechanism of action will drive a “natural progression” that will see the drug “move up in lines of therapy”.
According to Jefferies analysts, azetukalner’s efficacy results should allow the drug to “command a pricing premium and attract a sizeable market share, with the company calling $2bn+ peak sales a “conservative” figure.
Xenon currently predicts that azetukalner could reach the market by late 2027 to early 2028 – matching the 2027 forecast set by GlobalData, parent company of Clinical Trials Arena. If approved, William Blair, GlobalData and Jefferies all forecast that azetukalner will become a blockbuster drug.
